Market Overview

UPDATE: Citigroup Reiterates Illumina at Neutral on Valuation

Related ILMN
The 4 Companies Teaming Up For A New Tool To Fight Cancer
US Stock Futures Surge Ahead Of Economic Data

Citigroup maintained Illumina (NASDAQ: ILMN) at Neutral with a $51 price target.

Citigroup commented, "We expect the stock to be under pressure today as investors question the deal valuation/near-term $0.20 EPS dilution of the Verinata deal, the longer term impact of ILMN competing with its own customers (i.e., SQNM), and the level (if any) of Roche takeout premium to still ascribe to the stock. We remain on the sidelines on ILMN stock given the stock's current multiple and level of investment required/EPS power for the company in 2013."

Illumina closed at $54.76 on Friday.

Latest Ratings for ILMN

DateFirmActionFromTo
Sep 2014Morgan StanleyInitiates Coverage onEqual-weight
Aug 2014WedbushUpgradesNeutralOutperform
Aug 2014Stifel NicolausInitiates Coverage onBuy

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Reiteration Intraday Update Analyst Ratings

 

Related Articles (ILMN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters